Research preview · Not medical advice · Published with Drift0r’s permission · Permission is not endorsement · Not clinician-reviewed · Licensed clinicians must verify underlying records · Do not start, stop, or change treatment based on this material

Documented gaps and open questions (lead)

Research gaps first — not a ranked diagnosis list. Priority chips mean research priority, never clinical urgency.

1. CQ-001 [bone · high · don’t-miss] — Would paired bone formation markers (P1NP, bone-specific ALP ± osteocalcin), interpreted with preanalytical standards, help classify turnover before any long-term bone-agent class discussion?
2. CQ-002 [bone · high · don’t-miss] — On the next same-scanner DXA, can age-appropriate Z-scores be reported and can hip BMD change be interpreted against a facility-derived LSC? If vertebral fracture assessment (VFA) is considered, does the patient meet formal indication criteria rather than low BMD alone? Trabecular bone score (TBS), if discussed, is per ISCD generally for ages ≥40 with male fracture-risk evidence primarily studied above age 50 — this patient is ~38, so is TBS applicable now, or better deferred?
3. CQ-003 [renal_bone · high] — Is controlled calcium-flux phenotyping (sodium-aware 24h urine with stone profile + fasting urine Ca/Cr + paired serum Ca/PTH/PO4) appropriate to classify hypercalciuria mechanism?

+5 additional high-priority questions on /questions-for-clinicians/ (not repeated here for print density).

Record questions that still block wording

• UQ-0001 — What was the exact KIT assay for the reported negative result — specimen type, method (ASO-qPCR, ddPCR, NGS, other), laboratory, and limit of detection?
• UQ-0003 — Can original laboratory reports for total testosterone ≈34 ng/dL (reportedly ×2) be retrieved with dates, assay methods, and concurrent LH, FSH, prolactin, estradiol, SHBG?
• UQ-0006 — Do treating clinicians characterize L5 pars defects as fragility fractures meeting formal osteoporosis diagnostic criteria for a young male, or as stress/isthmic lesions?

+5 further record questions block launch-critical wording, and all 8 of them — plus the rest of the register — are listed on /questions/ (not repeated here for print density).

Selected documented anchors

• CLM-0003: DXA lumbar L3 Z-score −4.3 on 2025-06-16 at Site 1 (BMD 0.631 g/cm²); same-day L3 T-score −4.3 (Z-score preferred for males <50 per ISCD). [partially verified]
• CLM-0006: Total hip BMD fell from 0.836 to 0.802 g/cm² (compiled summary states −4.2%; recomputation (0.802−0.836)/0.836 ≈ −4.1%) between 2025-06-16 and 2026-06-19 on the same Site 1 scanner; compiled summary states LSC=0.027 g/cm² and calls the change significant at 95% confidence. [partially verified]
• CLM-0015: 24-hour urine calcium values 283 → 254 → 333 mg/24h (male; common threshold often 300 mg/day or 4 mg/kg — 2 of 3 collections below 300), with high urine sodium on latest panel (174 mmol/24h) and alkaline urine pH 6.53. Middle value (254 on 2025-09-30) was normal at the performing lab (ref 100–300) and high only against Litholink range 40–250; ranges differ by lab. [partially verified]
• CLM-0018: Historical total testosterone reported as low as ~34 ng/dL (narrative/clinical-context in summaries); earliest discrete tabulated total T values in endocrine summary begin 2021. [partially verified]
• CLM-0036: Babesia FISH (whole blood) positive on two specialty-lab draws (Jul 2023 and Feb 2024); Babesia PCR (B. microti and B. duncani) and immunoblot IgM/IgG negative on Jul 2023 panel. [partially verified]

Research only — not medical advice · Not clinician-reviewed · analysis v0.4.1

Research preview · Not medical advice · Published with Drift0r’s permission · Permission is not endorsement · Not clinician-reviewed · Licensed clinicians must verify underlying records · Do not start, stop, or change treatment based on this material

analysis v0.4.1 · evidence through 2026-08-10 · as of 2026-08-11 · review: published · patient approval: obtained · clinician review: not performed

Working hypotheses (research index — not diagnoses)

Ranked as a research index only. Lead with gaps above. Multi-model research synthesis is not clinical validation. Clinician review of this portfolio has not been performed.

1. H1 — Layered skeletal–metabolic–neurologic–immune stack (infection detachable) · medium
   Preferred multi-disease research architecture from Round-1 synthesis — a research organizing frame, not a single causal mechanism and not…
2. H2 — Monogenic / constitutional early-onset osteoporosis spectrum · medium
   Best single-primary research alternative (WNT1/LRP5/PLS3/mild OI spectrum; HPP low unless ALP truly low). Gene panel not performed. Relat…
3. H3 — Calcium-flux / incomplete bone-turnover phenotyping module · medium
   Ongoing calcium-flux research module (serial 24h urine Ca 283→254→333 mg/24h in a male; common male threshold often 300 mg/day or 4 mg/kg…

+2 additional model(s) on /working-model/ (omitted here for two-page density).

H-NULL (null model): several common processes may coexist without a single rare unifier — see working model.

Specialty LDT vs independent testing

• Babesia: signal FISH positive on two draws (Jul 2023, Feb 2024); reference Babesia PCR negative (same public summary set). NOT INDEPENDENTLY CONFIRMED (claims CLM-0036; channels not merged).
• Bartonella: signal Immunoblot IgM genus/species positive Jul 2023; later indeterminate/negative pattern; reference Bartonella PCR/FISH negative on whole blood (public summary). NOT INDEPENDENTLY CONFIRMED (claims CLM-0037; channels not merged).

Bone terminology for males under 50 emphasizes Z-scores and BMD below expected range for age. Infection limb detachable. No source PDFs are attached. Related routes (browser): how-this-could-be-wrong · prediction matrix.

Research only — not medical advice · Not clinician-reviewed · analysis v0.4.1